TG Therapeutics (TGTX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does TG Therapeutics (TGTX) do?
TG Therapeutics Inc (TGTX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells an intravenous antibody treatment for adults with relapsing forms of multiple sclerosis. Develops experimental cell therapies targeting progressive autoimmune diseases. TG Therapeutics sells an antibody therapy for multiple sclerosis that requires short one-hour maintenance infusions. It is worth $9.81B on the market and sold $898.03M over the last year.
- Market cap
- $9.81B
- P/E ratio
- 96.4×
- Annual sales
- $898.03M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 13, 2026
Brands and businesses behind TGTX
- Briumvi: A prescription antibody infusion that generates revenue from sales to treat adults with relapsing multiple sclerosis.
TGTX’s flags, in plain English
Each flag is a number from TG Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.
Stupid Cash
Can pay this year's bills 4.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 82.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Still Climbing
Sales up 426.7% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Debt Is Driving
Heavy debt, 132% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about TGTX
How big is TG Therapeutics?
TG Therapeutics’ market cap is $9.81B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $898.03M: what customers paid the company over the last year, before any costs.
What is TGTX’s P/E ratio?
TGTX’s P/E ratio is 96.4×. Investors pay about 96.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with TGTX?
The business relies heavily on revenue generated from a single commercial multiple sclerosis medicine. That is one risk on TG Therapeutics’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From TG Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TGTX’s filings on SEC.gov. The Margin Monkey is research, not advice.
